Impax Selects OmniComm To Conduct Phase III Study In Parkinson’s Disease
OmniComm has reported that Impax has selected its TrialMaster EDC solution for conducting a phase III study in patients with Parkinson’s Disease. Impax would use OmniComm’s TrialMaster EDC
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.